Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06042153 · ClinicalTrials.gov registry record · Phase 4
DIALYSIS-TIR Study
A Phase 4 study of Type 2 Diabetes and End Stage Renal Disease on Dialysis, sponsored by University of Texas Southwestern Medical Center.
- Active
- Registry status
- Phase 4
- Development phase
- 43
- Enrollment target
- 5
- Study locations
NCT06042153: Active Phase 4 study of Type 2 Diabetes and End Stage Renal Disease on Dialysis, sponsored by University of Texas Southwestern Medical Center.
NCT06042153 is a Phase 4 study of Type 2 Diabetes and End Stage Renal Disease on Dialysis that is active but no longer recruiting, run by University of Texas Southwestern Medical Center. The registered enrollment target is 43 participants, below the 3,924-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (99% lower). The trial reports 5 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06042153, a Phase 4 study of Type 2 Diabetes and End Stage Renal Disease on Dialysis, is active but no longer recruiting, sponsored by University of Texas Southwestern Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 43 participants
- Enrollment target
- 5
- Study locations
Study Summary
This study will look at control of blood sugar levels in persons with type 2 diabetes mellitus currently on chronic dialysis. Researchers will compare blood sugar levels in people taking semaglutide to people taking "dummy" medicine. The treatment participants get will be decided randomly. Participants will need to inject the study medication once a week. The study will last for 1 year and a month. Participants will be asked to wear a sensor that measures blood sugar levels for a period of 10 days at five different time points during the study.
Primary Outcome
Measured in percentage by Continuous glucose monitor (CGM)
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Semaglutide
Study Locations (5)
Texas
- Davita UT Southwestern - Oak Cliff - Dallas
- DaVita UT Southwestern - East Dallas - Dallas
- DaVita UT Southwestern - Preston - Dallas
- DaVita UT Southwestern - Irving - Irving
North Carolina
- University of North Carolina - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2023-12-05 |
| Est. Completion | 2028-09 |
| Phase | Phase 4 |
What the registry record for NCT06042153 still lists
NCT06042153 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 43 participants, a relatively small participant target, below the 3,924-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (99% lower).
The record links to 2 conditions, with Type 2 Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06042153 lists 5 locations in 2 states (Texas, North Carolina).
Frequently Asked Questions
What is clinical trial NCT06042153 about?
NCT06042153 is a clinical study titled "DIALYSIS-TIR Study". This study will look at control of blood sugar levels in persons with type 2 diabetes mellitus currently on chronic dialysis. Researchers will compare blood sugar levels in people taking semaglutide to people taking "dummy" medicine. The treatment participants get will be decided randomly. Particip...
What is the current status of trial NCT06042153?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 43 participants. The study started on 2023-12-05. Estimated completion is 2028-09.
What conditions does trial NCT06042153 study?
This clinical trial studies the following conditions: Type 2 Diabetes, End Stage Renal Disease on Dialysis.
What interventions are being tested in trial NCT06042153?
The interventions under investigation include: Placebo (DRUG), Semaglutide (DRUG).
Who is sponsoring clinical trial NCT06042153?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06042153 being conducted?
This trial has 5 study locations across North Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06042153's enrollment target sits among peer trials
43 223rd of 327 higher than 104 of 327 other Type 2 Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 2 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Mechanism of SGLT2 Inhibition in the Kidney
RECRUITING · Phase 4
-
GLUCOSE-MGH: Genetic Links Understood Through Challenge With Oral Semaglutide Exposure at MGH
RECRUITING · Phase 4
-
DiEtary Sodium Intake Effects on Ertugliflozin-induced Changes in GFR, reNal Oxygenation and Systemic Hemodynamics: the DESIGN Study, a Randomized, Placebo-controlled, Cross-over Study With Ertugliflozin in People With Type 2 Diabetes
RECRUITING · Phase 4
-
Glycemic and Weight Loss Effects of GLP-1R Agonist Therapy in Subjects With Spinal Cord Injury and Type 2 Diabetes
RECRUITING · Phase 4
-
Quantifying Hepatic Mitochondrial Fluxes in Humans
RECRUITING · Phase 4
-
PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT03850418 · 43 participants · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI